1. High-Flow Nasal Cannula Versus Noninvasive Ventilation as Initial Treatment in Acute Hypoxia: A Propensity Score-Matched Study.
- Author
-
Munroe ES, Prevalska I, Hyer M, Meurer WJ, Mosier JM, Tidswell MA, Prescott HC, Wei L, Wang H, and Fung CM
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Oxygen Inhalation Therapy methods, Oxygen Inhalation Therapy instrumentation, Cohort Studies, Acute Disease, Emergency Service, Hospital statistics & numerical data, Treatment Outcome, Noninvasive Ventilation methods, Noninvasive Ventilation instrumentation, Noninvasive Ventilation adverse effects, Propensity Score, Cannula, Hypoxia therapy, Hypoxia mortality, Respiratory Insufficiency therapy, Respiratory Insufficiency mortality
- Abstract
Importance: Patients presenting to the emergency department (ED) with hypoxemia often have mixed or uncertain causes of respiratory failure. The optimal treatment for such patients is unclear. Both high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) are used., Objectives: We sought to compare the effectiveness of initial treatment with HFNC versus NIV for acute hypoxemic respiratory failure., Design Setting and Participants: We conducted a retrospective cohort study of patients with acute hypoxemic respiratory failure treated with HFNC or NIV within 24 hours of arrival to the University of Michigan adult ED from January 2018 to December 2022. We matched patients 1:1 using a propensity score for odds of receiving NIV., Main Outcomes and Measures: The primary outcome was major adverse pulmonary events (28-d mortality, ventilator-free days, noninvasive respiratory support hours) calculated using a win ratio., Results: A total of 1154 patients were included. Seven hundred twenty-six (62.9%) received HFNC and 428 (37.1%) received NIV. We propensity score matched 668 of 1154 (57.9%) patients. Patients on NIV versus HFNC had lower 28-day mortality (16.5% vs. 23.4%, p = 0.033) and required noninvasive treatment for fewer hours (median 7.5 vs. 13.5, p < 0.001), but had no difference in ventilator-free days (median [interquartile range]: 28 [26, 28] vs. 28 [10.5, 28], p = 0.199). Win ratio for composite major adverse pulmonary events favored NIV (1.38; 95% CI, 1.15-1.65; p < 0.001)., Conclusions and Relevance: In this observational study of patients with acute hypoxemic respiratory failure, initial treatment with NIV compared with HFNC was associated with lower mortality and fewer composite major pulmonary adverse events calculated using a win ratio. These findings underscore the need for randomized controlled trials to further understand the impact of noninvasive respiratory support strategies., Competing Interests: Dr. Munroe was supported by grant number T32 HL 007749 (Multidisciplinary Training Program in Lung Disease), grant number F32 HL 172463 and grant number L30 HL 170379 (Loan Repayment Award) from the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI). This work was also supported in part by a grant from NIH (NINDS and NHLBI) for infrastructure for the Clinical Coordinating Center for the Strategies to Innovate EmeRgENcy Care Clinical Trials Network—2U24NS100659. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This article does not represent the views of the Department of Veterans Affairs or the U.S. government. Dr. Mosier has received travel support from Fisher & Paykel. The remaining authors have disclosed that they do not have any potential conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF